CN1981814A - Use and production for mulberry leaf in treatment of diabetes - Google Patents
Use and production for mulberry leaf in treatment of diabetes Download PDFInfo
- Publication number
- CN1981814A CN1981814A CN 200510122356 CN200510122356A CN1981814A CN 1981814 A CN1981814 A CN 1981814A CN 200510122356 CN200510122356 CN 200510122356 CN 200510122356 A CN200510122356 A CN 200510122356A CN 1981814 A CN1981814 A CN 1981814A
- Authority
- CN
- China
- Prior art keywords
- folium mori
- preparation
- mori extract
- extract according
- total
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012601 Diabetes mellitus Diseases 0.000 title claims abstract description 20
- 235000008708 Morus alba Nutrition 0.000 title abstract 2
- 240000000249 Morus alba Species 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title description 2
- 239000000284 extract Substances 0.000 claims abstract description 58
- 229930013930 alkaloids Natural products 0.000 claims abstract description 27
- 229930003944 flavones Natural products 0.000 claims abstract description 20
- 235000011949 flavones Nutrition 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 18
- 238000001035 drying Methods 0.000 claims abstract description 12
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N flavone Chemical compound O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229940079593 drugs Drugs 0.000 claims abstract description 3
- 239000012535 impurity Substances 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 68
- 238000002360 preparation method Methods 0.000 claims description 29
- 239000011347 resin Substances 0.000 claims description 17
- 229920005989 resin Polymers 0.000 claims description 17
- 150000002213 flavones Chemical class 0.000 claims description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 10
- 239000003729 cation exchange resin Substances 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- PPBRXRYQALVLMV-UHFFFAOYSA-N styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- -1 ZTCl+1 Polymers 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000003480 eluent Substances 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 150000002215 flavonoids Chemical class 0.000 claims description 5
- 229930003935 flavonoids Natural products 0.000 claims description 5
- 235000017173 flavonoids Nutrition 0.000 claims description 5
- 239000008394 flocculating agent Substances 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 229940023488 Pill Drugs 0.000 claims description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L Sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 229920001817 Agar Polymers 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- DJHJJVWPFGHIPH-OODMECLYSA-N Chitin Chemical compound O[C@@H]1C(NC(=O)C)[C@H](O)OC(CO)[C@H]1COC[C@H]1C(NC(C)=O)[C@@H](O)[C@H](COC[C@H]2C([C@@H](O)[C@H](O)C(CO)O2)NC(C)=O)C(CO)O1 DJHJJVWPFGHIPH-OODMECLYSA-N 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 claims description 2
- DIHKMUNUGQVFES-UHFFFAOYSA-N N,N,N',N'-tetraethylethane-1,2-diamine Chemical compound CCN(CC)CCN(CC)CC DIHKMUNUGQVFES-UHFFFAOYSA-N 0.000 claims description 2
- 241001597008 Nomeidae Species 0.000 claims description 2
- 239000004793 Polystyrene Substances 0.000 claims description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 230000000240 adjuvant Effects 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 238000011109 contamination Methods 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000003456 ion exchange resin Substances 0.000 claims description 2
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 235000010265 sodium sulphite Nutrition 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 150000003700 vitamin C derivatives Chemical class 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 1
- 150000003797 alkaloid derivatives Chemical class 0.000 abstract description 3
- 230000003405 preventing Effects 0.000 abstract description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 210000004369 Blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000004204 Blood Vessels Anatomy 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 210000002784 Stomach Anatomy 0.000 description 5
- 201000001421 hyperglycemia Diseases 0.000 description 5
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N Isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- LXBIFEVIBLOUGU-FSIIMWSLSA-N 1,5-Dideoxy-1,5-Imino-D-Mannitol Chemical compound OC[C@@H]1NC[C@@H](O)[C@H](O)[C@H]1O LXBIFEVIBLOUGU-FSIIMWSLSA-N 0.000 description 3
- LXBIFEVIBLOUGU-JGWLITMVSA-N 1-Deoxynojirimycin Natural products OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 210000003491 Skin Anatomy 0.000 description 3
- 229960001052 Streptozocin Drugs 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 210000001508 Eye Anatomy 0.000 description 2
- 101700033533 HP20 Proteins 0.000 description 2
- 210000003141 Lower Extremity Anatomy 0.000 description 2
- 210000000496 Pancreas Anatomy 0.000 description 2
- 101710029677 TIM22-2 Proteins 0.000 description 2
- 241001122767 Theaceae Species 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 201000001320 atherosclerosis Diseases 0.000 description 2
- 230000003143 atherosclerotic Effects 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000002218 hypoglycaemic Effects 0.000 description 2
- 230000000968 intestinal Effects 0.000 description 2
- 230000000291 postprandial Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 150000008494 α-glucosides Chemical class 0.000 description 2
- 210000004556 Brain Anatomy 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N Catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- 229940100626 Catechin Drugs 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229920001429 Chelating resin Polymers 0.000 description 1
- 229950001002 Cianidanol Drugs 0.000 description 1
- 208000004205 Diabetic Angiopathy Diseases 0.000 description 1
- 206010012680 Diabetic neuropathy Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 210000003414 Extremities Anatomy 0.000 description 1
- YZNNBIPIQWYLDM-HSUXUTPPSA-N Fagomine Chemical compound OC[C@H]1NCC[C@@H](O)[C@@H]1O YZNNBIPIQWYLDM-HSUXUTPPSA-N 0.000 description 1
- YZNNBIPIQWYLDM-ZLUOBGJFSA-N Fagomine Natural products OC[C@@H]1NCC[C@H](O)[C@H]1O YZNNBIPIQWYLDM-ZLUOBGJFSA-N 0.000 description 1
- 206010062060 Hyperlipidaemia Diseases 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 206010025482 Malaise Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- 206010052639 Nerve injury Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033775 Paraesthesia Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 208000008425 Protein Deficiency Diseases 0.000 description 1
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 1
- 229960001285 Quercetin Drugs 0.000 description 1
- 206010038435 Renal failure Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 description 1
- 206010068760 Ulcers Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000003712 anti-aging Effects 0.000 description 1
- 230000003064 anti-oxidating Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001925 catabolic Effects 0.000 description 1
- 229930016253 catechin Natural products 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 201000002342 diabetic polyneuropathy Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 235000020828 fasting Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 239000003316 glycosidase inhibitor Substances 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000011528 polyamide (building material) Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229930002344 quercetin Natural products 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Abstract
An extract of mulberry leaf contains general alkaloid and general flavone, and is prepared through extracting, removing impurities, concentrating, eluting, drying and mixing. It can be used to prepare the medicines for preventing and treating diabetes and its complications.
Description
Technical field
The present invention relates to a kind of Folium Mori extract and application and preparation method in preparation treatment diabetes and complication medicine thereof, belong to modern Chinese traditional medicine field.
Background technology
Diabetes are a kind of common endocrinopathyes, and its cause mainly is because due to inherited genetic factors and environmental factors such as dietetic life custom bad (surfeit, smart food etc.), quantity of motion deficiency, obesity and the stress etc.Along with the aging of world population, diabetes have become a kind of commonly encountered diseases, frequently-occurring disease, and sickness rate is remarkable ascendant trend.
Diabetes are that a class causes to have the chronic hyperglycemia of obvious heterogeneity and the syndrome that complication is formed by factors such as heredity, environment, immunity.Mainly be divided into two kinds on I type and II type, the insulin that type i diabetes (insulin dependent diabetes mellitus (IDDM)) patient pancreas produces seldom or does not fully produce insulin; Type ii diabetes (non-insulin-dependent diabetes mellitus) patient pancreas can continue to produce insulin, sometimes in addition insulin level surpass the normal person, yet body produces opposing to the effect of insulin, causes insulin to lack relatively.Based on noninsulin dependent II type, about 80% is the type ii diabetes patient.Long-term hyperglycemia infringement blood vessel, nerve and other internal organs structures, compound glycosyl material is deposited in little blood vessel wall, makes its thickening and easy to leak.The blood vessel wall thickening, the blood vessel amount of blood supply is fewer and feweri, and the blood vessel of especially arranging skin and nerve changes more obvious.Poor blood glucose control also can cause that fatty material raises in the blood, quickens atherosclerosis (forming speckle in blood vessel wall).In the diabetics, atherosclerosis is 2～6 times of non-diabetic persons, and men and women's both sexes all can take place.The inadequate circulatory blood volume of large and small blood vessel can be damaged heart, brain, two lower limb, eye, kidney, nerve, skin etc., makes wound healing slow.Just because of above reason, diabetics easily merges many severe chronic complication, and heart attack and apoplexy are very common; The vascular lesion of eyes can cause visual loss (diabetic retinopathy); Renal function is unusual, causes renal failure, needs dialysis treatment; Nervous lesion has several performances, and both hands, two lower limb, biped nerve damage (diabetic polyneuropathy) paraesthesia and acupuncture can occur or burn sample pain, myasthenia of limbs; If cutaneous nerve is impaired, patient can not feel extruding or variations in temperature, makes the skin may be injured repeatedly; SkBF is under-supply also can to cause ulcer, and wound healing is slow.
Folium Mori are as the raw material of medicine-food two-purpose, already in extensive use among the people.Since ancient times, the traditional Chinese medical science just is applied to its Chinese medicine as treatment diabete (diabetes that are equivalent to modern medicine) clinical, puts down in writing in the Compendium of Material Medica: " juice is fried in shallow oil Dai Ming, can only quench one's thirst "; " the ripe drink of frying in shallow oil of moxibustion quenches the thirst for tea ".Modern study shows, mainly contains steroidal and triterpenoid compound, flavone compound, alkaloid, aminoacid, organic acid and other chemical compounds in the Folium Mori.
Since the seventies year in last century, the Japan scholar got 1-deoxynojirimycin (DeoxyjirimicinDNJ) from plant, the polyhydroxylated alkaloid compounds is with its stereochemical structure multiformity, multiple biological activity, become the research focus, especially this compounds causes the very big interest of people as the analog of sugar and have glucoside inhibiting activity.Studies show that multiple glycosidase inhibitor such as 1-deoxynojirimycin (DNJ), fagomine etc. are arranged in the Folium Mori.Pharmacological research confirms, thereby the polyhydroxylated alkaloid compounds suppresses the absorption of small intestinal to disaccharidase to the active inhibitory action of disaccharides catabolic enzyme, reduces the peak value of post-prandial glycemia.Flavone compound has also been reported hypoglycemic activity in the Folium Mori, and the atherosclerotic infringement of reduction is arranged, and reduces small intestinal capillary permeability isoreactivity.Total alkaloids of Folium Mori and total flavones be as effective part group, not only can blood sugar lowering and improve carbohydrate tolerance and reduce effects such as atherosclerotic infringement simultaneously in addition, diabetic vascular complications there are prevention and therapeutical effect.
Application number is the Chinese patent of CN 01113191.8, " Preparation method and use with Chinese medicine extract of alpha-glucoside inhibiting activity " disclosed, this patent relates to from Chinese medicine Folium Mori, Ramulus Mori, Cortex Mori and Fructus Mori and prepares total alkaloids, does not still relate to the application as the extract of effective part group of total alkaloids of Folium Mori and total flavones.Application number is that the Chinese patent of CN 200410018677.4 discloses " medical composition and its use with alpha-glucoside inhibiting activity ", and this patent has related to the application in treatment diabetes, treatment hyperlipidemia, antioxidation and antiaging agent of total alkaloids for preparing in Chinese medicine Folium Mori, Ramulus Mori, Cortex Mori and the Fructus Mori and the compositions that adds flavone compound Quercetin, catechin and tea polyphenols.The invention provides a kind of method of alkaloid and flavone effective part and extract that this method obtains of from Folium Mori, obtaining simultaneously.
The objective of the invention is to, from Folium Mori, extract preparation total alkaloids and total flavones as effective part group, as the medicine of treatment and prevent diabetes and complication thereof.
Summary of the invention
The object of the invention is to provide a kind of Folium Mori extract, it is characterized in that wherein total alkaloids and content of total flavone sum are greater than 50%.
The present invention also provides the preparation method of said extracted thing.
Another object of the present invention is to provide the application of this Folium Mori extract in the preparation diabetes medicament.
For achieving the above object, the present invention is by the following technical solutions:
A kind of preparation method of Folium Mori extract may further comprise the steps:
1) extract: with Folium Mori is raw material, water, lower alcohol or moisture lower alcohol extraction;
2) remove impurity: extracting solution is concentrated, and concentrated solution precipitate with ethanol or adding flocculating agent make contamination precipitation, filter;
3) enrichment: filtrate is through cation exchange resin column, and effluent passes through macroporous resin column again;
4) eluting: be adsorbed in Folium Mori total flavonoids on the macroporous resin with moisture lower alcohol eluting, be adsorbed in total alkaloids of Folium Mori on the cation exchange resin with volatility aqueous slkali eluting;
5) drying: eluent is evaporated to dried, and drying is pulverized and promptly obtained Folium Mori total flavonoids and total alkaloids of Folium Mori respectively.
6) mix: resulting total flavones and total alkaloids are mixed, make total alkaloids and content of total flavone sum, promptly get Folium Mori extract of the present invention greater than 50%.
Obtain Folium Mori total flavonoids and total alkaloids of Folium Mori also can be further purified by polyamide and anion exchange resin respectively through said method.
Described extraction is C1-C5 with the carbon number of moisture lower alcohol, for example: methanol, ethanol, propanol, n-butyl alcohol, isobutanol etc.; Concentration is X, 0＜X≤95%, preferred 0＜X≤30%.
In the described removal step, it is X that the adding high concentration ethanol makes the solution concentration of alcohol, 40%≤X≤90%, preferred 50≤X≤60%.
In the described removal step, the flocculating agent of adding can be gelatin, chitosan, agar, ZTC1+1, chitin and derivant thereof, is preferably chitosan.
Described macroporous resin can be for any one or a few is the polarity or the non-polar resin of framework material in styrene, divinylbenzene, acrylate and the methacrylate.For example D101, D201, AB-8, HP-20, XAD-4 and XAD-16 etc.Be preferably styrene tyle macroporous adsorption resin.
Described cation exchange resin can be polystyrene or macroporous ion-exchange resin, for example 001X4,001X7,001X14.5, Dowex50, Amberlite IR120 or Amberlite252 etc.Preferred 001X4, the 001X7 type.
Described volatility alkali is the aqueous solution of 0.1%～1 ammonia, diethylamino, triethylamine, pyridine, is preferably 0.5% ammonia spirit.
Described eluting is C1-C5 with the carbon number of moisture lower alcohol, for example: methanol, ethanol, propanol, n-butyl alcohol, isobutanol etc.; Concentration is X, 45≤X≤100%, preferred 50≤X≤80%.
The drying means of Folium Mori extract is vacuum drying, lyophilization, spray drying etc., is preferably vacuum drying or lyophilization.
A kind of Folium Mori extract, this Folium Mori extract adopt method for preparing to obtain.
A kind of application of Folium Mori extract is used to described Folium Mori extract to prepare the application of the medicine aspect of treatment and prevent diabetes and complication thereof.
A kind of Folium Mori extract preparation, the described Folium Mori extract of said preparation is a main active, adds the pharmaceutics acceptable auxiliary, makes the pharmaceutics acceptable forms.Described adjuvant is selected from any one or a few in starch, microcrystalline Cellulose, sucrose, dextrin, lactose, Icing Sugar, glucose, sodium chloride, vitamin C, cysteine, citric acid and the sodium sulfite.
Described pharmaceutics acceptable forms is oral agents or injection, is tablet, pill, capsule, drop pill, liquid drugs injection, powder pin or transfusion.
When the Folium Mori extract that utilizes the present invention to obtain prepares the various dosage form of required medicine, can be according to the conventional production method preparation in pharmaceutics field.As this extract is mixed with one or more carriers, make corresponding dosage forms then.
Advantage of the present invention is: Folium Mori extract provided by the present invention, its preparation technology is simple, content is high, safety, easy operating, do not need High Temperature High Pressure and special installation, with low cost.
Describe technical solution of the present invention by the following examples in detail, do not limit practical range of the present invention with this.
The specific embodiment
Embodiment 1
Folium Mori 10kg pulverizes, with 30% alcohol reflux 3 times, and 50L at every turn; Merge 30% ethanol extract, be evaporated to 10L, proportion is 1.18, adds 95% ethanol 20L, makes concentration of alcohol reach about 60%, leaves standstill 24h, the filtering precipitation; After supernatant concentration was removed alcohol, thin up was crossed the D101 resin column to 100L, and column volume is 10L, and last sample after washing 30L merges effluent and water lotion; D101 resin reuse 60% ethanol elution 50L, 60% ethanol elution concentrate the back drying under reduced pressure and promptly get total flavones 130g (content is 57%); Effluent and water lotion add hydrochloric acid transfer pH4 after, cross 001 * 7 polystyrolsulfon acid hydrogen type cation exchange resin of 10L, be washed to colourless after, with the ammonia eluting 80L of 0.5N, ammonia eluent concentrate drying promptly gets total alkaloids 65g (content is 65%); Mix the Folium Mori extract that total flavones and total alkaloids promptly get indication of the present invention.
The Folium Mori extract 100g that obtains adds starch 15000g, microcrystalline Cellulose 70g, and with 50%7 alcohol granulations, tabletting gets tablet, and every is 10mg.
Embodiment 2
Folium Mori 5kg pulverizes, with 50% alcohol reflux 3 times, and 10L at every turn; Merge 50% ethanol extract, be evaporated to 10L, proportion is 1.17, adds 95% ethanol 7L, makes concentration of alcohol reach about 70%, leaves standstill 24h, the filtering precipitation; After supernatant concentration was removed alcohol, thin up was crossed the AB8 resin column to 100L, and column volume is 5L, and last sample after washing 20L merges effluent and water lotion; AB8 resin reuse 70% ethanol elution 30L, 70% ethanol elution concentrate the back drying under reduced pressure and promptly get total flavones 70g (content is 62.5%); Effluent and water lotion add hydrochloric acid transfer pH5 after, cross the 001X14.5 polystyrolsulfon acid hydrogen type cation exchange resin of 6L, be washed to colourless after, with the ammonia eluting 40L of 0.5N, ammonia eluent concentrate drying promptly gets total alkaloids 32.5g (content is 57%); Mix the Folium Mori extract that total flavones and total alkaloids promptly get indication of the present invention.
Embodiment 3
Folium Mori 1kg pulverizes, with 70% alcohol reflux 3 times, and 5L at every turn; Merge 70% ethanol extract, be evaporated to 1.5L, proportion is 1.16, adds the flocculating agent chitosan, leaves standstill 24h, the filtering precipitation; After supernatant concentration was removed alcohol, thin up was crossed the HP20 resin column to 10L, and column volume is 2L, and last sample after washing 5L merges effluent and water lotion; HP20 resin reuse 60% ethanol elution 5L, 60% ethanol elution concentrate the back drying under reduced pressure and promptly get total flavones 11g; Effluent and water lotion add hydrochloric acid transfer pH4 after, cross 001 * 7 polystyrolsulfon acid hydrogen type cation exchange resin of 10L, be washed to colourless after, with the ammonia eluting 8L of 0.5N, ammonia eluent concentrate drying promptly gets total alkaloids 5g (content is 73%); Mix the Folium Mori extract that total flavones and total alkaloids promptly get indication of the present invention.
Embodiment 4
Normal mouse post-prandial glycemia time graph: the Male Kunming strain mice body weight is 22-25g, overnight fasting, irritate stomach starch 10g/kg and irritate the Folium Mori extract 150mg/kg that stomach embodiment 1 obtains simultaneously, 0min, 30min, 60min, 90min, 120min survey blood sugar level, result such as accompanying drawing after the administration.
Embodiment 5
40 of Kunming mouses are divided into 40 groups at random, and 10 every group, male and female half and half, (1) matched group (distilled water); (2) hyperglycemia model group (distilled water); (3) Folium Mori extract low dose group (50mg/kg); (4) Folium Mori extract high dose group (150mg/kg).Except that the normal control group, all the other respectively organize lumbar injection streptozotocin (200mg/kg), survey blood glucose (12h on an empty stomach) after 72 hours, then with (2)-(4) group, according to the balanced group of adjusting of blood glucose value.Irritate stomach by above dosage simultaneously and give the Folium Mori extract that embodiment 1 obtains, continuous 7 days, empty stomach 12h before the administration in the 7th day, 1h measures blood glucose after the last administration.The results are shown in Table
The table Folium Mori extract brings out the influence of mice hyperglycemia to streptozotocin
| Group | Dosage (mg/kg) | Blood glucose before the medicine | Blood glucose behind the medicine | Rate of change |
| (mmol/L) | (mmol/L) | (％) | ||
| Normal control group hyperglycemia model group Folium Mori extract (low dose group) Folium Mori extract (high dose group) | --- --- 50 150 | 4.73±1.01 9.34±2.23** 9.60±2.68 9.76±2.60 | 4.86±1.02 9.49±2.04** 7.59±2.41 7.39±1.80** | +3.1±7.8 +2.1±5.8 -21.3±5.5 -23.8±7.8 |
Annotate: data are X ± SD (n=10) in (1) table
Compare P＜0.01 with normal group; Compare P＜0.05, * * P＜0.01 (t check) with model group.
Conclusion: mouse peritoneal registration streptozotocin can make blood sugar increasing, and after giving Folium Mori extract, have hypoglycemic effect.Wherein dosage is that (150mg/kg) compares with model group, and difference has the significance meaning.
Claims (19)
1, a kind of Folium Mori extract is characterized in that wherein total alkaloids and content of total flavone sum are greater than 50%.
2, a kind of preparation method of Folium Mori extract may further comprise the steps:
1) extract: with Folium Mori is raw material, water, lower alcohol or moisture lower alcohol extraction;
2) remove impurity: extracting solution is concentrated, and concentrated solution precipitate with ethanol or adding flocculating agent make contamination precipitation, filter;
3) enrichment: filtrate is through macroporous resin column, and effluent passes through cation exchange resin column again;
4) eluting: be adsorbed in Folium Mori total flavonoids on the macroporous resin with moisture lower alcohol eluting, be adsorbed in total alkaloids of Folium Mori on the cation exchange resin with volatility aqueous slkali eluting;
5) drying: eluent is evaporated to dried, and drying is pulverized and promptly obtained Folium Mori total flavonoids and total alkaloids of Folium Mori respectively.
6) mix: resulting total flavones and total alkaloids are mixed, make total alkaloids and content of total flavone sum, promptly get Folium Mori extract of the present invention greater than 50%.
3, the preparation method of Folium Mori extract according to claim 2 is characterized in that: described extraction is C1-C5 with the carbon number of moisture lower alcohol, and concentration is X, 0＜X≤95%.
4, the preparation method of Folium Mori extract according to claim 3 is characterized in that: described extraction is X with the concentration of moisture lower alcohol, 0＜X≤30%.
5, the preparation method of Folium Mori extract according to claim 2 is characterized in that: it is X that described precipitate with ethanol makes the solution concentration of alcohol, 40%≤X≤90%.
6, the preparation method of Folium Mori extract according to claim 2 is characterized in that: it is X that described precipitate with ethanol makes the solution concentration of alcohol, 50≤X≤60%.
7, the preparation method of Folium Mori extract according to claim 2 is characterized in that: described flocculating agent can be one or more in gelatin, chitosan, agar, ZTCl+1, chitin and the derivant thereof.
8, the preparation method of Folium Mori extract according to claim 2 is characterized in that: described macroporous resin can be so that any one or a few is the polarity or the non-polar resin of framework material in styrene, divinylbenzene, acrylate and the methacrylate.
9, the preparation method of Folium Mori extract according to claim 8 is characterized in that: described macroporous resin is the styrene type resin.
10, the preparation method of Folium Mori extract according to claim 2 is characterized in that: described cation exchange resin can be polystyrene or macroporous ion-exchange resin.
11, the preparation method of Folium Mori extract according to claim 2 is characterized in that: described volatility alkali is the aqueous solution of 0.1%～1% ammonia, diethylamino, triethylamine, pyridine.
12, the preparation method of Folium Mori extract according to claim 11 is characterized in that: described volatility alkali is 0.5% ammonia spirit.
13, the preparation method of Folium Mori extract according to claim 2 is characterized in that: described eluting is C1-C5 with the carbon number of moisture lower alcohol, and concentration is X, 40≤X＜100%.
14, the preparation method of Folium Mori extract according to claim 13 is characterized in that: described concentration is X, 50≤X≤80%.
15, a kind of Folium Mori extract is characterized in that: any one described method prepares in this Folium Mori extract employing claim 1 to 14.
16, a kind of Folium Mori extract preparation is characterized in that: said preparation is a main active with the described Folium Mori extract of claim 15, adds the pharmaceutics acceptable auxiliary, makes the pharmaceutics acceptable forms.
17, Folium Mori extract preparation according to claim 16, it is characterized in that: described adjuvant is selected from any one or a few in starch, microcrystalline Cellulose, sucrose, dextrin, lactose, Icing Sugar, glucose, sodium chloride, vitamin C, cysteine, citric acid and the sodium sulfite.
18, Folium Mori extract according to claim 17 is characterized in that: described pharmaceutics acceptable forms is oral agents or injection, is tablet, pill, capsule, drop pill, liquid drugs injection, powder pin or transfusion.
19, a kind of application of Folium Mori extract is characterized in that: the described Folium Mori extract of claim 18 is used to prepare prevention and treats the extremely medicament of complication of diabetes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510122356 CN1981814A (en) | 2005-12-15 | 2005-12-15 | Use and production for mulberry leaf in treatment of diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510122356 CN1981814A (en) | 2005-12-15 | 2005-12-15 | Use and production for mulberry leaf in treatment of diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1981814A true CN1981814A (en) | 2007-06-20 |
Family
ID=38164844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510122356 Pending CN1981814A (en) | 2005-12-15 | 2005-12-15 | Use and production for mulberry leaf in treatment of diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1981814A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101780147A (en) * | 2010-03-12 | 2010-07-21 | 广西药用植物园制药厂 | Anti-inflammatory and hypoglycemic mulberry leave extract and preparation method of preparation thereof |
| CN101869605A (en) * | 2010-07-02 | 2010-10-27 | 安徽济人药业有限公司 | Method for extracting and separating mulberry leaf flavone and alkaloid composite |
| CN102228513A (en) * | 2011-06-29 | 2011-11-02 | 江苏大学 | Medicinal composition for treating diabetes or diabetic complications and preparation method thereof |
| CN101278977B (en) * | 2008-03-31 | 2012-05-30 | 广州唐百服生物科技有限公司 | Method for extracting main active components of mulberry leaf and application of its extract |
| CN102872203A (en) * | 2012-10-30 | 2013-01-16 | 广州牌牌生物科技有限公司 | Technology for synchronously producing total flavone, total alkaloid and total polysaccharide in mulberry bark |
| CN105535112A (en) * | 2015-12-29 | 2016-05-04 | 浙江省农业科学院 | Extraction technology of hypoglycemic medicinal active substances of mulberry leaves and mulberries and formula |
| CN107362200A (en) * | 2017-08-08 | 2017-11-21 | 南京中医药大学 | A kind of method that isolating alkaloids and flavones are extracted from mulberry leaf |
| CN110393738A (en) * | 2019-08-27 | 2019-11-01 | 北京五和博澳药业有限公司 | A kind of plant extraction process |
-
2005
- 2005-12-15 CN CN 200510122356 patent/CN1981814A/en active Pending
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101278977B (en) * | 2008-03-31 | 2012-05-30 | 广州唐百服生物科技有限公司 | Method for extracting main active components of mulberry leaf and application of its extract |
| CN101780147A (en) * | 2010-03-12 | 2010-07-21 | 广西药用植物园制药厂 | Anti-inflammatory and hypoglycemic mulberry leave extract and preparation method of preparation thereof |
| CN101869605A (en) * | 2010-07-02 | 2010-10-27 | 安徽济人药业有限公司 | Method for extracting and separating mulberry leaf flavone and alkaloid composite |
| CN101869605B (en) * | 2010-07-02 | 2012-05-02 | 安徽济人药业有限公司 | Method for extracting and separating mulberry leaf flavone and alkaloid composite |
| CN102228513A (en) * | 2011-06-29 | 2011-11-02 | 江苏大学 | Medicinal composition for treating diabetes or diabetic complications and preparation method thereof |
| CN102228513B (en) * | 2011-06-29 | 2013-04-17 | 江苏大学 | Medicinal composition for treating diabetes or diabetic complications and preparation method thereof |
| CN102872203A (en) * | 2012-10-30 | 2013-01-16 | 广州牌牌生物科技有限公司 | Technology for synchronously producing total flavone, total alkaloid and total polysaccharide in mulberry bark |
| CN105535112A (en) * | 2015-12-29 | 2016-05-04 | 浙江省农业科学院 | Extraction technology of hypoglycemic medicinal active substances of mulberry leaves and mulberries and formula |
| CN107362200A (en) * | 2017-08-08 | 2017-11-21 | 南京中医药大学 | A kind of method that isolating alkaloids and flavones are extracted from mulberry leaf |
| CN110393738A (en) * | 2019-08-27 | 2019-11-01 | 北京五和博澳药业有限公司 | A kind of plant extraction process |
| CN110393738B (en) * | 2019-08-27 | 2022-09-20 | 北京五和博澳药业股份有限公司 | Plant extraction method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1981814A (en) | Use and production for mulberry leaf in treatment of diabetes | |
| CN103041118B (en) | Composition with effects of reducing blood sugar and reducing blood lipid | |
| CN103750107B (en) | Health-care product with blood glucose reducing function | |
| CN103446385A (en) | Traditional Chinese medicine preparation for treating diabetic complications | |
| CN1931228B (en) | Lysimachia herb total flavone extract and its preparation process | |
| CN101301401B (en) | Camellia effective ingredients and extracting method and use thereof | |
| CN103301200A (en) | Astragalus membranaceus powder medicament as well as extraction method and use thereof | |
| CN101940616A (en) | Preparation method of effective part of Clinopodium chinense (Benth.) O. Kuntze for preventing and treating diabetes and medicine application thereof | |
| CN101732491B (en) | Medicament for treating hypertension, hyperlipoidemia, high blood viscosity and anti-aging | |
| CN1240407C (en) | Chinese-medicinal extract with alpha-glucosidase inhibitor activity, and its preparing process and application | |
| CN102233056A (en) | Chinese medicine composition for treating diabetes and syndromes of diabetes | |
| CN101933965A (en) | Mugwort extract and preparation process thereof, and application in controlling postmeal gucose | |
| CN105477126A (en) | Traditional Chinese medicine extract composition used for treating depression and preparation method and application thereof | |
| CN101297823A (en) | Medicament for preventing and treating Alzheimer's disease | |
| CN103536615A (en) | Preparation method of didymin and isosakuranetin, and application thereof in anti-diabetic medicine | |
| CN102631482B (en) | Chinese medicinal composition for preventing and treating diabetes and complications | |
| CN109528782A (en) | Ginkgo biloba p.e has the application of the drug for the treatment of or health care as synergist in preparation to sleep disturbance disease | |
| CN1985917B (en) | Medicine composition for reducing blood sugar, reducing blood fat and controlling diabetes complication | |
| CN102579587B (en) | Traditional Chinese medicine composition for preventing and treating diabetes and complications thereof | |
| CN101822705A (en) | Total platycodin and application of monomer platycodin D in antialcoholic drugs | |
| CN113476561A (en) | Traditional Chinese medicine formula for treating diabetes | |
| CN100534461C (en) | Pharmaceutical composition for treating diabetes and impaired glucose tolerance and preparation method thereof | |
| CN100500174C (en) | Medicine composition used for lowering blood-sugar, preparation method and use thereof | |
| CN103385931A (en) | Blood-sugar-lowering medicine composition | |
| CN101884723A (en) | Anemarrhena and goldthread composition preparation used for treating diabetes and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |